Ivermectin and Fatty Liver Disease: What Research Shows and What It Does Not

Interest in ivermectin and fatty liver disease comes largely from laboratory and animal research suggesting that ivermectin can influence pathways involved in how the liver stores and processes fat. Some experiments have reported less fat accumulation in cultured liver cells and in certain mouse models after ivermectin exposure. However, these findings do not show that ivermectin treats fatty liver disease in people, because convincing human clinical trials for this purpose are lacking. Ivermectin is an antiparasitic medicine with established uses for specific infections, not an established treatment for metabolic dysfunction-associated steatotic liver disease (MASLD), the condition previously commonly called nonalcoholic fatty liver disease or NAFLD. There are also liver-safety considerations because ivermectin is processed by the liver and has rarely been associated with clinically apparent liver injury. This article separates the promising biological findings from the clinical evidence, explains the safety questions, and puts ivermectin into the context of current fatty liver treatment.

• •What Is Fatty Liver Disease, and Why Is Ivermectin Being Studied?
• •What Does Research on Ivermectin and Fatty Liver Disease Show?
• •What Does the Research Not Show?
• •Is Ivermectin Safe for Someone With Fatty Liver Disease?
• •What Treatments Have Better Evidence for Fatty Liver Disease?
• •Why Preclinical Ivermectin Findings Still Matter
• •When to Seek Medical Advice About Fatty Liver or Ivermectin
• •Conclusion
• •Frequently Asked Questions

What Is Fatty Liver Disease, and Why Is Ivermectin Being Studied?

Fatty liver disease means that excess fat has accumulated within liver cells. One major form is now called metabolic dysfunction-associated steatotic liver disease, or MASLD. It is commonly associated with metabolic problems such as excess weight, type 2 diabetes, abnormal blood fats, and high blood pressure.

Some people with MASLD have mainly excess liver fat, while others develop inflammation and liver-cell injury. The more active form is called metabolic dysfunction-associated steatohepatitis, or MASH, previously known as NASH. Over time, MASH can lead to fibrosis, meaning scar tissue, and in some people eventually cirrhosis.

Ivermectin became scientifically interesting in this area for a reason unrelated to its usual antiparasitic action. Researchers found that it could interact with metabolic signalling pathways, including a liver-related receptor called farnesoid X receptor, or FXR. FXR helps regulate bile acids, fats, glucose, and several genes involved in metabolism.

That biological observation raised an important research question: could ivermectin or related molecules alter the processes that cause fat to build up in the liver?

The question is scientifically reasonable. It is not, however, the same as showing that ivermectin is an effective medicine for people with fatty liver disease.

What Does Research on Ivermectin and Fatty Liver Disease Show?

The strongest positive findings so far come from preclinical research—studies performed in cells or animals rather than clinical trials involving patients. These experiments can identify mechanisms worth investigating, but they sit much earlier on the evidence pathway than randomized human trials.

Laboratory research in liver cells

A 2019 study examined ivermectin in HepG2 cells, a human liver-cancer cell line commonly used in laboratory research. Researchers first created a laboratory model of steatosis, or fat accumulation, by exposing the cells to palmitic acid.

In that model, ivermectin reduced triglyceride accumulation and altered genes involved in making and breaking down fat. The investigators reported effects consistent with reduced lipogenesis—the creation of new fat—and increased activity of FXR-related pathways.

The 2019 laboratory study of ivermectin and liver fat  is useful evidence for understanding a possible mechanism. But these were cells growing under controlled laboratory conditions, not people with MASLD. A drug concentration that changes fat metabolism in a dish may behave very differently in a human body.

Research in mice

Earlier research published in Scientific Reports examined ivermectin and several related avermectin compounds in diabetic mice with substantial liver-fat accumulation. Ivermectin-treated animals showed lower hepatic triglyceride levels and markedly reduced fat accumulation in liver tissue compared with untreated controls.

Researchers linked some of these changes to FXR activation and changes in genes involved in hepatic fat production and metabolism.

These results make ivermectin scientifically interesting as a research molecule. Mouse models can help researchers identify biological pathways and potential drug targets, but successful results in mice frequently do not translate into safe and effective treatments for humans.

What different levels of ivermectin research can—and cannot—tell us about fatty liver disease

Evidence type	What has been observed	What it can tell us	What it cannot establish
Liver-cell experiments	Ivermectin reduced triglyceride accumulation and affected lipid-related pathways in a steatosis model	Ivermectin can influence fat metabolism under laboratory conditions	That it reduces liver fat or improves health outcomes in patients
Mouse research	Some diabetic mice showed reduced hepatic fat after ivermectin treatment	A biological effect can occur in a whole-animal experimental model	Human effectiveness, appropriate dosing, long-term safety, or clinical benefit
Human fatty-liver trials	Adequate clinical evidence establishing ivermectin as a MASLD/MASH treatment is lacking	There is currently no solid clinical basis for using ivermectin to treat MASLD	Benefit cannot be assumed from cell or animal results
Regulatory/guideline evidence	Current MASLD/MASH recommendations address lifestyle, metabolic risk factors, and approved therapies for selected patients	What has reached sufficient clinical evidence for routine care	They do not validate ivermectin as a fatty-liver therapy

A drug can reduce fat inside liver cells or improve fatty liver in mice and still fail to help patients. For ivermectin, the missing bridge is convincing human clinical evidence showing meaningful benefit with acceptable safety.

What Does the Research Not Show?

Current evidence does not show that ivermectin is a proven treatment for fatty liver disease in humans.

That distinction matters because laboratory research is sometimes described online using words such as “reverses fatty liver” or “treats NAFLD.” Such language goes beyond what the evidence supports.

There is no established human treatment effect

The available preclinical studies do not tell us whether people taking ivermectin would experience:

• a meaningful reduction in liver fat;

• improvement in liver inflammation;

• regression of fibrosis;

• lower risk of cirrhosis;

• fewer liver-related complications; or

• better long-term survival.

Those outcomes require properly designed human studies.

A clinical treatment also needs a well-tested dose, treatment duration, patient-selection strategy, monitoring plan, and understanding of interactions and adverse effects. Laboratory and animal experiments do not provide that information for people with MASLD.

A plausible mechanism is not clinical proof

The FXR findings are biologically interesting because FXR is involved in liver metabolism. But finding that a molecule interacts with an important pathway does not establish that the molecule is suitable as a medicine for a particular disease.

Clinical drug development frequently begins with promising mechanisms. Many candidates never become treatments because they later prove ineffective, unsafe, difficult to dose, or inferior to existing options.

It is therefore more accurate to describe ivermectin as a subject of preclinical fatty-liver research, rather than as an investigational treatment supported by established human efficacy.

Is Ivermectin Safe for Someone With Fatty Liver Disease?

Having fatty liver does not automatically mean that ivermectin will cause liver injury, but existing liver disease is a reason to treat medication decisions carefully. Ivermectin is metabolized in the liver, primarily through CYP3A4, and its prescribing information includes reports of hepatitis, increased liver enzymes, and increased bilirubin after marketing.

The U.S. National Institutes of Health LiverTox resource describes ivermectin as generally associated with a low rate of mild, self-limited aminotransferase elevations and with very rare reports of clinically apparent liver injury. It classifies ivermectin as a possible rare cause of mild acute liver injury rather than a drug commonly associated with serious hepatotoxicity.

The NIH LiverTox review of ivermectin  also notes that reported liver injury has generally been mild and self-limited. Rare does not mean impossible, particularly when a person already has liver disease or is taking several medicines.

It is also important to separate veterinary ivermectin products from medicines formulated for human use. Veterinary preparations may differ in concentration and formulation and should not be used as substitutes for prescribed human medicines.

Practical dos and don'ts when ivermectin and liver health are both concerns

Do	Don't
Tell your clinician if you have MASLD, MASH, cirrhosis, abnormal liver tests, or another liver condition	Do not take ivermectin specifically to treat fatty liver based only on cell or animal studies
Review prescription medicines, supplements, and other products with a healthcare professional	Do not assume that “experimental” means clinically effective or safe
Use ivermectin only for an appropriate medical indication and according to professional guidance	Do not copy a dose from an online post or animal study
Seek advice if new symptoms appear after starting a medicine	Do not use veterinary ivermectin products for human self-treatment
Follow the monitoring plan recommended for your underlying liver condition	Do not stop prescribed medicines simply because a liver test changes without speaking with the treating clinician

What Treatments Have Better Evidence for Fatty Liver Disease?

Management of MASLD focuses first on the metabolic factors that drive the disease and on identifying people at risk of progressive fibrosis. Lifestyle changes—including nutritious eating patterns, physical activity, and gradual weight reduction where appropriate—remain central to management. European clinical guidance, for example, recommends sustained weight loss in adults with overweight and MASLD because progressively greater weight reductions are associated with improvements in liver fat, inflammation, and fibrosis.

Treatment has also moved beyond the older idea that no medicines are approved for MASH. In the United States, the FDA approved resmetirom in March 2024 for certain adults with noncirrhotic MASH/NASH and moderate-to-advanced fibrosis, alongside diet and exercise.

In August 2025, the FDA also granted accelerated approval to semaglutide, marketed as Wegovy, for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. AASLD subsequently updated its practice guidance to address patient selection and monitoring for semaglutide treatment.

The AASLD guidance for MASLD and MASH management  reflects this evolving clinical landscape. These treatments are intended for selected patients rather than everyone who has liver fat, so fibrosis stage, metabolic health, other medical conditions, and individual risks matter.

None of these developments provide evidence for substituting ivermectin. Instead, they illustrate the level of human clinical data and regulatory review required before a treatment becomes part of routine liver care.

Why Preclinical Ivermectin Findings Still Matter

Saying that ivermectin is not an established fatty-liver treatment does not mean the research is worthless. Preclinical studies can reveal biological pathways that lead researchers toward new therapies.

The FXR findings are a good example. If a known compound activates a pathway that improves lipid handling in experimental models, researchers may study the pathway further, modify the chemical structure, or develop new molecules designed to retain desirable metabolic effects while improving safety and selectivity.

That is a normal part of drug discovery. Sometimes an existing medicine eventually finds an entirely new clinical role, a process called drug repurposing.

But repurposing still requires clinical development. Researchers need to establish whether the drug reaches the relevant tissues at safe concentrations, whether the effect occurs in humans, whether it improves meaningful outcomes, and whether benefits outweigh risks.

Until those steps are completed successfully for ivermectin in fatty liver disease, its preclinical results should be viewed as hypothesis-generating rather than treatment-directing.

When to Seek Medical Advice About Fatty Liver or Ivermectin

Fatty liver disease can be present for years without obvious symptoms, so decisions should not depend on how well someone feels. People with known MASLD or persistently abnormal liver tests should discuss their fibrosis risk and appropriate follow-up with a healthcare professional.

Medical advice is particularly important before taking ivermectin if you have known liver disease, take several medicines, are pregnant or breastfeeding, or are considering ivermectin for a purpose for which it has not been recommended.

Seek prompt medical assessment after taking a medicine if you develop symptoms that could suggest significant liver or drug-related problems, such as yellowing of the skin or eyes, very dark urine, persistent vomiting, marked abdominal pain, unusual confusion, or severe weakness. These symptoms can have many causes and should not be self-diagnosed.

If ivermectin is genuinely needed for a parasitic infection, having fatty liver does not by itself answer whether treatment is appropriate. The indication, severity of liver disease, other medicines, and individual risks should be considered by the treating clinician.

Conclusion

Research into ivermectin and fatty liver disease has produced interesting findings in cultured liver cells and mouse models, particularly involving fat metabolism and FXR signalling. What is missing is the evidence that matters most for treatment decisions: convincing human trials showing that ivermectin safely improves MASLD, MASH, fibrosis, or long-term clinical outcomes. Ivermectin therefore should not be viewed as an established fatty-liver treatment. If you have fatty liver disease, focus on evidence-based assessment and management with a qualified healthcare professional, and discuss any proposed ivermectin use before taking it—especially when liver function or other medicines may affect safety.

Frequently Asked Questions

1. Can ivermectin treat fatty liver disease?

No clinical evidence currently establishes ivermectin as a treatment for fatty liver disease in people. Laboratory and mouse studies suggest effects on liver-fat metabolism, but those results cannot predict patient benefit. Human trials would be needed before ivermectin could be considered an evidence-based MASLD treatment.

2. Has ivermectin been shown to reduce liver fat?

Ivermectin has reduced fat or triglyceride accumulation in certain laboratory liver-cell and mouse experiments. That is preclinical evidence rather than proof of a therapeutic effect in patients. There is not adequate human evidence showing that taking ivermectin reduces liver fat in people with MASLD.

3. Why are researchers interested in ivermectin for fatty liver?

Researchers found that ivermectin can affect metabolic pathways involved in liver-fat regulation, including FXR signalling. That makes the molecule useful for studying how liver metabolism might be modified. It does not mean ivermectin has been established as a safe or effective treatment for fatty liver disease.

4. Can ivermectin damage the liver?

Ivermectin-related clinically apparent liver injury appears to be rare, but it has been reported. Mild increases in liver enzymes can also occur, and ivermectin is metabolized in the liver. People with liver disease should therefore discuss its use with a healthcare professional rather than self-treating.

5. Can I take ivermectin if I already have fatty liver?

Fatty liver alone does not determine whether ivermectin is appropriate. The reason for treatment, degree of liver impairment, other medicines, and individual health factors all matter. If ivermectin is needed for an established indication, a clinician can assess those issues and decide whether monitoring is appropriate.

6. What should I use instead of ivermectin for fatty liver disease?

Treatment depends on the type and severity of liver disease rather than replacing ivermectin with one universal medicine. Lifestyle and metabolic-risk management remain fundamental, while selected patients with MASH and significant fibrosis may qualify for approved therapies. A clinician can assess fibrosis and appropriate treatment options.